Trial reportThoracic cancer2020
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07.
Trial report in Thoracic cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review.Advances in therapy · 2021Pooled it
- Efficacy of Immune Checkpoint Inhibitors in Rare Tumours: A Systematic Review.Frontiers in immunology · 2021Pooled it
- Evaluation of the Effectiveness and Safety Profile of First-Line Immune Checkpoint Inhibitors Combined with Chemotherapy in Pulmonary Sarcomatoid Carcinoma.Lung Cancer (Auckland, N.Z.) · 2025Trial
- Prevalence of High Programmed Death-Ligand 1 Expression in Pulmonary Sarcomatoid Carcinoma: A Systematic Review and Meta-Analysis.JTO clinical and research reports · 2026Review
- Successful treatment with tepotinib followed by pembrolizumab in pulmonary pleomorphic carcinoma harbouring aOncology letters · 2026Article
- The pathogenesis and therapeutic management of rare pulmonary sarcomatoid carcinoma: a narrative review.Translational lung cancer research · 2025Review
- The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group.Cancer research and treatment · 2025Article
- Sequential anlotinib and camrelizumab combination therapy achieves exceptional survival in multi-driver mutated, TMB-low/PD-L1-low/MSS pulmonary sarcomatoid carcinoma: case report and literature review.Frontiers in immunology · 2025Review
- Efficacy of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma.Translational lung cancer research · 2024Article
- Biological characteristics and clinical treatment of pulmonary sarcomatoid carcinoma: a narrative review.Translational lung cancer research · 2024Review
- Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma.JTO clinical and research reports · 2024Article
- Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers.Therapeutic advances in medical oncology · 2024Review
- Targeted therapy for rare lung cancers: Status, challenges, and prospects.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Review
- Demographics and Clinicopathologic Profile of Pulmonary Sarcomatoid Carcinoma with Survival Analysis and Genomic Landscape.Cancers · 2023Article
- Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review.Frontiers in oncology · 2023Article
- Anlotinib combined with chemotherapy and immunotherapy for advanced pulmonary sarcomatoid cancer: a case report and literature review.Annals of translational medicine · 2022Article
- Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study.Therapeutic advances in medical oncology · 2022Article
- Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art.Journal of oncology · 2022Review
- Major pathological response after neoadjuvant immunotherapy in esophageal spindle cell carcinoma: A case report.Thoracic cancer · 2021Article
- A Long-Term Survival Case Report of a Patient with Pulmonary Sarcomatoid Carcinoma Accompanied by Brain Metastasis: Implications for Immunotherapy.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 9 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary sarcomatoid carcinoma (PSC) is rare with a poor outcome and is resistant to conventional cytotoxic chemotherapy. The efficacy and safety of durvalumab and tremelimumab for treating recurrent or metastatic PSCs were assessed by a nonrandomized, open-label, phase II study.
methodsA total of 18 patients with recurrent or metastatic PSC received 1500 mg of durvalumab and 75 mg of tremelimumab every four weeks, followed by 750 mg of durvalumab every two weeks until the disease progressed, or an unacceptable toxicity level was reached. The primary endpoint was the objective response rate (ORR). The secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity. Genomic profiling of PSC by next-generation sequencing (NGS) and determination of peripheral blood lymphocyte subsets using flow cytometry were performed for exploratory analysis.
resultsA total of 15 out of 18 patients were evaluated for the analysis of the primary endpoint. At the data cutoff point, the ORR of 26.7% (95% confidence interval [CI]: 7.8-55.1) was achieved with the median follow-up duration of 12.0 months (range, 8.4-16.1). Median PFS and OS were 5.9 months (95% CI: 1.1-11.9) and 15.4 months (95% CI: 11.1-not reached), respectively. Treatment-related adverse events (AEs) of any grade were reported in 16 patients; the most common AEs were pruritus (n = 5), pneumonitis (n = 4), and rash (n = 4). Treatment was discontinued in two patients due to AEs of grade ≥ 3.
conclusionsDurvalumab and tremelimumab demonstrated clinical benefit with a prolonged survival and manageable toxicity profile in patients with recurrent or metastatic PSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.